• Avalo outlined an IL-1β pipeline led by abdakibart (AVTX-009) for moderate-to-severe hidradenitis suppurativa, citing positive Phase 2 topline data.
• LOTUS Phase 2 met its primary endpoint at week 16; combined HiSCR75 was 42.5% versus 25.6% for placebo (p=0.004).
• Combined HiSCR50 was 61.7% versus 40.7% for placebo (p=0.0009); dosing evaluated included 150 mg Q2W or 300 mg Q4W.
• Presentation cited about 500 patients studied across Phase 1 and 2; no adverse events related to neutropenia, serious infections, or opportunistic infections.
• AVTX-010, a long-acting next-generation anti-IL-1β monoclonal antibody, is expected to advance to IND in 1H 2027; cash runway projected into 2029 following USD 431.3 million financing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avalo Therapeutics Inc. published the original content used to generate this news brief on June 16, 2026, and is solely responsible for the information contained therein.